Health-care companies slipped as vaccine makers remained under pressure. Shares of Novavax plunged by 8%, compounding losses in the wake of the vaccine developer's earnings report. Rival Moderna lost ...
A third dose of COVID-19 vaccine offered essential workers some protection from developing long COVID during Omicron variant ...
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Hosted on MSN14h
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call TranscriptThis strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...
Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback